Log in
OTCMKTS:MEDIF

MediPharm Labs Stock Forecast, Price & News

$0.49
+0.04 (+8.96 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.45
Now: $0.49▼
$0.49
50-Day Range
$0.40
MA: $0.56▼
$0.71
52-Week Range
$0.40
Now: $0.49▼
$3.41
Volume508,784 shs
Average Volume323,206 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MediPharm Labs Corp., together with its subsidiaries, produces and sells pharmaceutical-grade cannabis oil and concentrates for derivative products in Canada and Australia. It also provides cannabis contract processing services to licensed producers and growers; and tolling services to licensed cultivators in Canada. In addition, the company supplies purified cannabis concentrate raw materials and product formulations for ready-to-sell advanced cannabis products. Further, it engages in the real estate business. The company was founded in 2015 and is headquartered in Barrie, Canada.

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.20 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MEDIF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.medipharmlabs.com
Phone705-719-7425
Employees230

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
$0.49
+0.04 (+8.96 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MEDIF News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDIF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MediPharm Labs (OTCMKTS:MEDIF) Frequently Asked Questions

How has MediPharm Labs' stock price been impacted by Coronavirus (COVID-19)?

MediPharm Labs' stock was trading at $1.53 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MEDIF stock has decreased by 68.2% and is now trading at $0.4866.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of MediPharm Labs?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediPharm Labs in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for MediPharm Labs or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than MediPharm Labs?

Wall Street analysts have given MediPharm Labs a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MediPharm Labs wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for MEDIF?

5 brokerages have issued twelve-month target prices for MediPharm Labs' shares. Their forecasts range from $1.00 to $1.75. On average, they expect MediPharm Labs' stock price to reach $1.56 in the next twelve months. This suggests a possible upside of 221.1% from the stock's current price.
View analysts' price targets for MediPharm Labs.

Are investors shorting MediPharm Labs?

MediPharm Labs saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 5,806,800 shares, an increase of 26.3% from the October 31st total of 4,598,000 shares. Based on an average daily trading volume, of 469,500 shares, the short-interest ratio is currently 12.4 days.
View MediPharm Labs' Short Interest.

Who are some of MediPharm Labs' key competitors?

Some companies that are related to MediPharm Labs include (THCX.V) (THCX), 31444 (GLH), 438280 (ACG), 815446 (HC), Abacus Health Products (ABAHF), Acreage (ACRGF), Althea Group Holdings Limited (AGH.AX) (AGH), Applied Biosciences (APPB), AusCann Group Holdings Ltd (AC8.AX) (AC8), Ayr Strategies (AYRSF), Bio-Rad Laboratories (BIO), Blueberries Medical (BBM), Can B (CANB), Cannara Biotech (LOVE) and CannPal Animal Therapeutics Limited (CP1.AX) (CP1).
View all competitors.

Who are MediPharm Labs' key executives?

MediPharm Labs' management team includes the following people:
  • Mr. Patrick McCutcheon, Founder, CEO & Chairman
  • Mr. Keith Strachan, Co-Founder, Pres & Director
  • Mr. Robert Kwon, Chief Financial Officer
  • Ms. Sybil Taylor, Chief Marketing Officer
  • Ms. Laura Lepore, VP of Investor Relations & Communications
  • Mr. Ahmed Shehata, Gen. Counsel & Head of Corp. Devel.
  • Mr. Brett Moon, VP of Sales
  • Ms. Lorna Willner, Director of HR
  • Mr. Warren Everitt, Chief Exec. Officer of Asia Pacific
  • Mr. Kirk Binns, Exec. VP of Global Accounts

What is MediPharm Labs' stock symbol?

MediPharm Labs trades on the OTCMKTS under the ticker symbol "MEDIF."

How do I buy shares of MediPharm Labs?

Shares of MEDIF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MediPharm Labs' stock price today?

One share of MEDIF stock can currently be purchased for approximately $0.49.

What is MediPharm Labs' official website?

The official website for MediPharm Labs is www.medipharmlabs.com.

How can I contact MediPharm Labs?

The company can be reached via phone at 705-719-7425.

This page was last updated on 12/5/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.